Diabetes:
Indications for: GVOKE
Severe hypoglycemia in diabetics.
Adults and Children:
<2yrs: not established. Give by SC inj into lower abdomen, outer thigh, or outer upper arm. May repeat after 15mins if no response. 2–<12yrs (<45kg): 0.5mg; (≥45kg): 1mg. ≥12yrs: 1mg.
GVOKE Contraindications:
Pheochromocytoma. Insulinoma.
GVOKE Warnings/Precautions:
Previously undiagnosed pheochromocytoma; risk of substantial increase in BP. If hypoglycemia develops after treatment, give oral or IV glucose. Conditions with insufficient hepatic glycogen (eg, starvation, adrenal insufficiency, chronic hypoglycemia); treat with glucose. Necrolytic migratory erythema (due to continuous infusion). Glucagonoma: if suspected, test prior to initiation and monitor during therapy. Pregnancy. Nursing mothers.
GVOKE Classification:
Antihypoglycemic.
GVOKE Interactions:
May cause transient increase in BP and pulse with β-blockers. Antagonized by indomethacin. May potentiate warfarin.
Adverse Reactions:
Adults: nausea, vomiting, inj site edema raised ≥1mm, headache; children: nausea, hypoglycemia, vomiting, headache, abdominal pain, hyperglycemia, inj site discomfort and reaction, urticaria; allergic reactions.
Generic Drug Availability:
NO
How Supplied:
Prefilled syringes, autoinjectors (HypoPen)—1, 2; Kit (0.2mL)—1 (single-dose vial and syringe)
